Chemomab Therapeutics Ltd. (CMMB): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2020-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$11.13M

Year ended 2025-12-31

2018-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$11.13M	n/m	2026-03-23, From 2025-01-01
2024-12-31	-$15.39M	n/m	2026-03-23, From 2024-01-01
2023-12-31	-$23.61M	n/m	2026-03-23, From 2023-01-01
2022-12-31	-$20.44M	n/m	2025-04-04, From 2022-01-01
2021-12-31	-$12.61M	n/m	2024-03-28, From 2021-01-01
2020-12-31	-$5.28M	n/c	2022-03-30, From 2020-01-01
2019-12-31	-$16.55M	n/m	2021-03-09, From 2019-01-01
2018-12-31	-$14.44M	n/a	2020-03-17, From 2018-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Chemomab Therapeutics Ltd. (CMMB)	2025-12-31	-$11.13M	n/m
CalciMedica, Inc. (CALC)	2025-12-31	-$21.21M	n/m
Exicure, Inc. (XCUR)	2025-12-31	-$8.56M	n/m
NRX Pharmaceuticals, Inc. (NRXP)	2024-12-31	-$10.64M	n/m
PMGC Holdings Inc. (ELAB)	2025-12-31	-$6.38M	n/m
Cellectar Biosciences, Inc. (CLRB)	2025-12-31	-$23.12M	n/m
Cingulate Inc. (CING)	2025-12-31	-$17.41M	n/m
Synlogic, Inc. (SYBX)	2025-12-31	-$4.36M	n/m
Imunon, Inc. (IMNN)	2025-12-31	-$14.18M	n/m

Compare CMMB, CALC, XCUR, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗